(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Israel scales back use of top missile interceptors as Iran barrages persist - 210 Setting up camp Shelters That Offer Both Excellence and Isolation
- 3A Timeline of Rising Antisemitism in Australia
- 4Interstellar comet 3I/ATLAS' journey through our solar system, in photos
- 54 Coolers for Present day Kitchens
- Popular Film Areas: A Worldwide Manual for Film Enchantment
- A definitive Burger Confrontation: Which One Rules?
- Islamabad: Iran allows 20 Pakistani ships through Strait of Hormuz
- The most effective method to Make a Dazzling Site in 5 Basic Advances
- 10 Demonstrated Tips to Expand Your New Android Cell phone: A Thorough Aide
- UK can legally stop shadow fleet tankers, ministers believe
- California warns of death cap mushrooms outbreak resulting in 3 deaths
- Move. Cheer. Dance. Do the wave. How to tap into the collective joy of 'we mode'
- How stripping diversity, equity and inclusion from health care may make Americans sicker
